ABIVAX vs Amneal Pharmaceuticals
ABIVAX (ABVX), health care, and Amneal Pharmaceuticals (AMRX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Amneal Pharmaceuticals is worth $7.4B on the stock market and ABIVAX $7.2B: Amneal Pharmaceuticals is valued at 2% more. Over the past year ABIVAX's share price has moved -26.5% and Amneal Pharmaceuticals's +83.5%.
Key facts
- ABIVAX market value
- $7.2B
- Amneal Pharmaceuticals market value
- $7.4B
- Amneal Pharmaceuticals P/E
- 52.8
- Amneal Pharmaceuticals revenue
- $3BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | ABIVAX | Amneal Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.2Blower | $7.4Bhigher |
| Revenue | — | $3B |
| Earnings | -$372.9Mlower | $72.1Mhigher |
| Employees | 98lower | 8,700higher |
| Total assets | $648.3Mlower | $3.7Bhigher |
| Valuation | ||
| P/E | — | 52.8 |
| P/S | — | 2.4 |
| P/B | — | 13.8 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | — | 13.1% |
| Balance sheet | ||
| Net assets | $505.1Mhigher | -$70.8Mlower |
| Total liabilities | $143.3Mlower | $3.7Bhigher |
| Total debt | — | $2.6B |
| Cash on hand | $573.3Mhigher | $282Mlower |
| Price change | ||
| Today | -1.81%lower | -0.52%higher |
| 1 year | -26.5%lower | +83.5%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
ABIVAX only (4)
- Peter Kolchinsky1.3%
- Doug Silverman0.4%
- Andrew Spokes0.1%
- Lee Ainslie<0.1%
Amneal Pharmaceuticals only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio. Who owns ABVX
More on ABIVAX
Further comparisons
ABIVAX against its closest peers
Amneal Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, ABIVAX or Amneal Pharmaceuticals?
By market value, Amneal Pharmaceuticals is the larger: $7.4B against $7.2B for ABIVAX.
Which superinvestors own both ABIVAX and Amneal Pharmaceuticals?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold ABIVAX and 0 hold Amneal Pharmaceuticals.
Cite this page
Funkfolio, “ABIVAX vs Amneal Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-amrx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.